$UTHR

AI Analysis

Generated on May 11, 2026

AI Score
76/ 100
Buy$UTHR

United Therapeutics

$UTHRNASDAQHealthcareLarge-Cap

United Therapeutics develops therapies for pulmonary arterial hypertension and organ transplantation.

Market Cap
$14.0B
Revenue (TTM)
$2.8B
+12.0%
Net Income (TTM)
$1.0B
+15.0%
EPS (TTM)
$22.00
P/E Ratio
12.0
Dividend Yield
0.0%
52-Week Range
$220-$350
Beta
0.52
Dimension Scores
Fundamental
78
Technical
72
Sentiment
74
Risk / Reward
76
Momentum
70
FundTechSentRiskMome
Financial Health
Profitability
83strong
Growth
73moderate
Liquidity
84strong
Solvency
80strong
Efficiency
76strong

Valuation, technical analysis, investment thesis, risk assessment and more for $UTHR

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.